Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6411 posts found.

blue_jeans

Strong early data on haemophilia gene therapy boosts Biomarin

July 28, 2016 Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a

Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …
News
johnnolech

John Lechleiter to step down as Lilly CEO

July 27, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter

Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …
News
ian_campbell

Innovate UK appoints first director of Health and Life Sciences

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ian Campbell, Innovate UK, appointment, health and life sciences

Ian Campbell has been named by Innovate UK as its first director for Health and Life Sciences. Innovate UK is …
Appointment

BMS names Fouad Namouni as new oncology development head

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Appointment
needles

Valeant receives complete response letter from FDA on glaucoma drug

July 22, 2016 Medical Communications, Sales and Marketing FDA, Glaucoma, Valeant

Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA rejecting their new drug application …
News
merckwindow

MSD faces delay in C. diff drug approval as FDA requests more data

July 22, 2016 Medical Communications, Research and Development C diff, FDA, MSD, Merck

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …
News

Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug

July 22, 2016 Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001

Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
News
clinical_trial_4

Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan

July 22, 2016 Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab

Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …
News
stocks1

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

July 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
Feature

Nice rejects United Therapeutics’ cancer drug

July 15, 2016 Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma

The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
News

Bayer adds extra $2 billion to Monsanto bid

July 15, 2016 Medical Communications, Sales and Marketing Bayer, monsanto

German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …
News

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
News
teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

July 15, 2016 Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
News
lab

Shares drop at Santhera after FDA requires more trial data DMD drug

July 15, 2016 Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera

Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …
News
celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 
News
The Gateway to Local Adoption Series

Latest content

Closing the immunisation gap: partnership working that delivered at scale

June 5, 2026

Phase 2 study explores imaging approach for interstitial lung disease

June 5, 2026

Laverock secures funding for gene-control platform development

June 4, 2026

LifeArc and Elpida partner to advance gene therapies for ultra-rare childhood diseases

June 3, 2026

Well Pharmacy and Alzheimer’s Society launch dementia partnership

June 2, 2026